TL;DR
Get workout gear delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Two reviews found no clear increase in most measured maternal or perinatal outcomes after GLP-1 exposure around conception or early pregnancy. The evidence remains limited, and researchers say the findings do not establish safety or change advice to stop treatment before planned conception.
Two reviews of studies on GLP-1 receptor agonists around pregnancy found no clear increase in most measured adverse maternal or perinatal outcomes, but the researchers said the findings do not establish that the drugs are safe during pregnancy. The results offer limited reassurance for inadvertent exposure before conception or early in pregnancy, while current advice to stop the drugs before a planned pregnancy remains in place.
A systematic review and meta-analysis of 10 studies covering more than 2.1 million pregnancies found no clearly detectable increase in miscarriage or intrauterine death, congenital anomalies, preterm birth, hypertensive disorders, gestational diabetes, abnormal fetal growth, or excess gestational weight gain among women exposed to GLP-1 drugs in the period around conception, compared with women who were not exposed. The review was published in the journal Med.
The analysis found a lower pooled estimate for preeclampsia among exposed women, with an odds ratio of 0.87 and a 95% confidence interval of 0.78 to 0.98. The authors cautioned that this result came from only two datasets and should be interpreted carefully. They also said differences in how exposure was defined, possible residual confounding, and small numbers of studies for some outcomes limit what can be concluded.
A second review, presented at the European Association for the Study of Diabetes annual meeting and published in Lancet Obstetrics, Gynaecology, & Women’s Health, included more than 40,000 women, primarily with type 2 diabetes. It found no increased congenital anomaly risk when treatment was stopped during the first trimester. Early pregnancy loss was more common in exposed women in two studies, but the researchers said the result was difficult to interpret because the largest study combined miscarriage and pregnancy termination.
Exposure Findings Do Not Change Advice
GLP-1 drugs are used for diabetes and other indications, and the source report says their use has expanded. The reviews examined outcomes after exposure around conception or early pregnancy, but they do not establish that continuing treatment during pregnancy is safe.
The researchers behind the larger review said the results may offer limited reassurance after inadvertent exposure, while advising against interpreting them as support for treatment during pregnancy. Patients who discover a pregnancy while taking a GLP-1 drug should consult their clinician about stopping treatment and managing their care.
Current Guidance and Evidence Gaps
GLP-1 receptor agonists are not approved for use during pregnancy. According to the source report, product labeling recommends stopping them at least two months before planned conception, although that guidance rests on limited human data. The new analyses examine observed past exposures; they are not controlled trials designed to establish safety.
The EASD review also informed an international consensus statement on GLP-1 use before, during, and after pregnancy in women with diabetes. Claire Meek of the University of Leicester said the group proposed clinical targets and strategies to help women understand when and how to stop treatment safely. She said contraception is strongly recommended while taking the drugs, and that treatment should stop in early pregnancy if conception occurs. The consensus authors said evidence remains scarce for use in type 1 diabetes, gestational diabetes, and during lactation.
“The findings may provide limited reassurance following inadvertent exposure before conception or during early pregnancy, but they should not be interpreted as supporting continued treatment during pregnancy.”
— Asma Khalil, MD, MSc, and colleagues
Limits of the Pregnancy Data
The studies cannot determine whether GLP-1 drugs cause or prevent the outcomes measured. Researchers cited variation in exposure definitions, residual confounding, and limited evidence for several outcomes. The preeclampsia estimate came from two datasets, while the early pregnancy loss signal in the second review combined miscarriage and termination in its largest contributing study, making its meaning uncertain.
The available evidence also leaves questions about specific drugs, doses, timing, and patient groups. The source report says direct evidence is especially scarce for women with type 1 diabetes and for use during lactation. The reviews concern past practice and may not fully describe the effects of current prescribing patterns.
More Evidence and Clinical Guidance
The cited researchers said guidance to stop GLP-1 receptor agonists at least two months before planned conception should remain unchanged. Meek’s group recommends contraception while taking the drugs and stopping treatment if pregnancy occurs, with a clinician helping manage next steps. The review authors called for larger, more robust studies and better reporting of sex-disaggregated data.
The source report specified no further study results or changes to product labeling. The consensus statement provides guidance for women with diabetes before, during, and after pregnancy; evidence for several uses remains limited.
Key Questions
Do these studies show that GLP-1 drugs are safe during pregnancy?
No. The reviews found no clear increase in most measured outcomes, but the authors said the evidence does not establish safety and does not support continuing treatment during pregnancy.
What should someone do when planning a pregnancy?
The source report says labeling recommends stopping GLP-1 receptor agonists at least two months before planned conception. Patients should discuss medication changes and diabetes care with their clinician.
What did the second review find about early pregnancy loss?
It reported more early pregnancy loss among exposed women, with a risk ratio of 1.31 across two studies. The researchers cautioned that the result was difficult to interpret because miscarriage and termination were combined in the largest contributing study.
Are GLP-1 drugs approved for use during pregnancy?
No. The source report says GLP-1 drugs are not currently approved for use during pregnancy.
Source: rss
Evergreen bestsellers Picks
bestsellers
As an affiliate, we earn on qualifying purchases.
